StreetInsider.com News Articles

Form SCHEDULE 13G NOVAVAX INC Filed by: STATE STREET CORP

Fri, 07 Aug 2026 10:26:00 -0400

si-local-file:///var/storage/secattach/20260807/26888967.html

Form SCHEDULE 13G NOVAVAX INC Filed by: STATE STREET CORP

Fri, 07 Aug 2026 10:26:00 -0400

si-local-file:///var/storage/secattach/20260807/26888967.html

Form S-8 NOVAVAX INC

Thu, 06 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260806/26883249.html

Form S-8 NOVAVAX INC

Thu, 06 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260806/26883249.html

Novavax (NVAX) Tops Q2 EPS by 8c

Thu, 06 Aug 2026 08:09:47 -0400

Novavax (NASDAQ: NVAX) reported Q2 EPS of ($0.32), $0.08 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $57 million versus the consensus estimate of $52.06 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.

Form 8-K NOVAVAX INC For: Aug 06

Thu, 06 Aug 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260806/26879332.html

Form 8-K NOVAVAX INC For: Aug 06

Thu, 06 Aug 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260806/26879332.html

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Thu, 06 Aug 2026 08:00:00 -0400

Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point
Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment
Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a $75 million milestone payment to Novavax
Multiple partner-led experiments with Matrix-M are currently underway in a wide array

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Thu, 06 Aug 2026 08:00:00 -0400

Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point
Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment
Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a $75 million milestone payment to Novavax
Multiple partner-led experiments with Matrix-M are currently underway in a wide array

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Thu, 06 Aug 2026 08:00:00 -0400

Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point
Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment
Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a $75 million milestone payment to Novavax
Multiple partner-led experiments with Matrix-M are currently underway in a wide array

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Thu, 06 Aug 2026 08:00:00 -0400

Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point
Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment
Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a $75 million milestone payment to Novavax
Multiple partner-led experiments with Matrix-M are currently underway in a wide array

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Thu, 06 Aug 2026 08:00:00 -0400

Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point
Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment
Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a $75 million milestone payment to Novavax
Multiple partner-led experiments with Matrix-M are currently underway in a wide array

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Thu, 06 Aug 2026 08:00:00 -0400

Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point
Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment
Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a $75 million milestone payment to Novavax
Multiple partner-led experiments with Matrix-M are currently underway in a wide array

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Thu, 06 Aug 2026 08:00:00 -0400

Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point
Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment
Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a $75 million milestone payment to Novavax
Multiple partner-led experiments with Matrix-M are currently underway in a wide array

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Thu, 06 Aug 2026 08:00:00 -0400

Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point
Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment
Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a $75 million milestone payment to Novavax
Multiple partner-led experiments with Matrix-M are currently underway in a wide array

Form 10-Q NOVAVAX INC For: Jun 30

Thu, 06 Aug 2026 07:50:00 -0400
si-local-file:///var/storage/secattach/20260806/26878997.html

Form 10-Q NOVAVAX INC For: Jun 30

Thu, 06 Aug 2026 07:50:00 -0400
si-local-file:///var/storage/secattach/20260806/26878997.html

Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026

Thu, 30 Jul 2026 07:00:00 -0400

GAITHERSBURG, Md., July 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Following the release, Company management will host a webcast and conference call at 8:30 a.m. Eastern Time (ET) to discuss financial results and operational highlights.
Conference call details:

Date:
August

Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026

Thu, 30 Jul 2026 07:00:00 -0400

GAITHERSBURG, Md., July 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Following the release, Company management will host a webcast and conference call at 8:30 a.m. Eastern Time (ET) to discuss financial results and operational highlights.
Conference call details:

Date:
August

Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026

Thu, 30 Jul 2026 07:00:00 -0400

GAITHERSBURG, Md., July 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Following the release, Company management will host a webcast and conference call at 8:30 a.m. Eastern Time (ET) to discuss financial results and operational highlights.
Conference call details:

Date:
August

Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026

Thu, 30 Jul 2026 07:00:00 -0400

GAITHERSBURG, Md., July 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Following the release, Company management will host a webcast and conference call at 8:30 a.m. Eastern Time (ET) to discuss financial results and operational highlights.
Conference call details:

Date:
August

Form 4 NOVAVAX INC For: Jun 18 Filed by: Rodgers Richard J

Tue, 23 Jun 2026 19:59:00 -0400
si-local-file:///var/storage/secattach/20260623/26681029.html

Form 4 NOVAVAX INC For: Jun 18 Filed by: Rodgers Richard J

Tue, 23 Jun 2026 19:59:00 -0400
si-local-file:///var/storage/secattach/20260623/26681029.html

Form 4 NOVAVAX INC For: Jun 18 Filed by: King Rachel K.

Tue, 23 Jun 2026 19:57:00 -0400
si-local-file:///var/storage/secattach/20260623/26681026.html

Form 4 NOVAVAX INC For: Jun 18 Filed by: King Rachel K.

Tue, 23 Jun 2026 19:57:00 -0400
si-local-file:///var/storage/secattach/20260623/26681026.html